FLUDEOXYGLUCOSE F 18
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- FLUDEOXYGLUCOSE F 18
- Generic name
- FLUDEOXYGLUCOSE F-18
- Manufacturer
- UIHC-P E T IMAGING CENTER
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 4842b836-1a7c-4417-ab8d-aa37bf7065f8
- SPL ID
- ea94086a-dfc3-31b1-e053-2a95a90abb8a
- Version
- 5
- Effective date
- 2022-10-09
- Source export date
- 2026-09-28
- Source partition
- 9
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0009-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/6784607726c827491ceaeab30d843632e0660ee8008c535197be5ed9e1e52201/drug-label-0009-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:58:17
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 203990 | derived:openfda.application_number |
| application number | ANDA203990 | openfda.application_number | |
| brand name | FLUDEOXYGLUCOSE F 18 | openfda.brand_name | |
| generic name | FLUDEOXYGLUCOSE F-18 | openfda.generic_name | |
| manufacturer name | UIHC-P E T IMAGING CENTER | openfda.manufacturer_name | |
| ndc | package | 24417-001-30 | openfda.package_ndc |
| ndc | product | 24417-001 | openfda.product_ndc |
| ndc11 | package | 24417000130 | derived:openfda.package_ndc |
| spl id | ea94086a-dfc3-31b1-e053-2a95a90abb8a | id | |
| spl set id | 4842b836-1a7c-4417-ab8d-aa37bf7065f8 | set_id | |
| unii | 0Z5B2CJX4D | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Radiation risks: use smallest dose necessary for imaging ( 5.1 ). Blood glucose abnormalities: may cause suboptimal imaging ( 5.2 ). 5.1 Radiation Risks Radiation-emitting products, including Fludeoxyglucose F 18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker [ see Dosage and Administration (2.5) ]. 5.2 Blood Glucose Abnormalities In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to Fludeoxyglucose F 18 Injection administration.
warnings and cautions
5.1 Radiation Risks Radiation-emitting products, including Fludeoxyglucose F 18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker [ see Dosage and Administration (2.5) ].
warnings and cautions
5.2 Blood Glucose Abnormalities In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to Fludeoxyglucose F 18 Injection administration.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS Hypersensitivity reactions with pruritus, edema and rash have been reported in the post-marketing setting. Have emergency resuscitation equipment and personnel immediately available. Hypersensitivity reactions have occurred; have emergency resuscitation equipment and personnel immediately available ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact UIHC - P E T Imaging Center at 319-356-1616 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.